These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15877316)

  • 21. AIDS vaccine trial disappointing.
    Science; 1996 Apr; 272(5260):341. PubMed ID: 8602519
    [No Abstract]   [Full Text] [Related]  

  • 22. Vaccines. From Brazil and France: a vaccine against HIV may lower viral load.
    TreatmentUpdate; 2005; 17(1):10-1. PubMed ID: 17228459
    [No Abstract]   [Full Text] [Related]  

  • 23. Changing treatment concepts.
    Katlama C
    HIV Med; 2001 Apr; 2(2):65-7. PubMed ID: 11737380
    [No Abstract]   [Full Text] [Related]  

  • 24. Sometimes help may not be enough.
    Lederman MM; Douek DC
    AIDS; 2003 May; 17(8):1249-51. PubMed ID: 12819528
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report from the 12th Retrovirus Conference. HIV/AIDS in resource-limited settings.
    del Rio C; Friedland GH
    AIDS Clin Care; 2005 Apr; 17(4):39-40. PubMed ID: 15875314
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
    Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
    AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immune-based therapies and HIV infection].
    Weiss L
    Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV hope ride on therapeutic vaccine.
    AIDS Read; 2005 Jul; 15(7):332. PubMed ID: 16044573
    [No Abstract]   [Full Text] [Related]  

  • 30. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
    Longo O; Tripiciano A; Fiorelli V; Bellino S; Scoglio A; Collacchi B; Alvarez MJ; Francavilla V; Arancio A; Paniccia G; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Vaccine; 2009 May; 27(25-26):3306-12. PubMed ID: 19208456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines. From Israel: a T-cell vaccine.
    TreatmentUpdate; 2005; 17(1):11-2. PubMed ID: 17228460
    [No Abstract]   [Full Text] [Related]  

  • 34. Twenty years of HIV-1 research: what the future holds.
    Imami N; Gotch F
    Nat Immunol; 2003 Jun; 4(6):501. PubMed ID: 12774067
    [No Abstract]   [Full Text] [Related]  

  • 35. Report from the 12th Retrovirus Conference. Treatment interruption and other novel treatment strategies.
    Henry K
    AIDS Clin Care; 2005 Apr; 17(4):35. PubMed ID: 15875308
    [No Abstract]   [Full Text] [Related]  

  • 36. Groundhog day.
    Kresge KJ; Noble S
    IAVI Rep; 2007; 11(2):1-6. PubMed ID: 20210115
    [No Abstract]   [Full Text] [Related]  

  • 37. Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise.
    Fruth U
    Vaccine; 2009 Mar; 27(14):1989-96. PubMed ID: 19146900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
    Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remune rejected. (will a manual recount be required?).
    Martinez LJ
    Res Initiat Treat Action; 2000 Dec; 6(4):23-4. PubMed ID: 11708171
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
    Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
    HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.